ES2198447T3 - Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis. - Google Patents

Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis.

Info

Publication number
ES2198447T3
ES2198447T3 ES95937658T ES95937658T ES2198447T3 ES 2198447 T3 ES2198447 T3 ES 2198447T3 ES 95937658 T ES95937658 T ES 95937658T ES 95937658 T ES95937658 T ES 95937658T ES 2198447 T3 ES2198447 T3 ES 2198447T3
Authority
ES
Spain
Prior art keywords
tofa
dopamine
receptor
ner
receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95937658T
Other languages
English (en)
Spanish (es)
Inventor
Eitan Friedman
M. Katharine Holloway
Gideon A. Rodan
Azriel Schmidt
Robert L. Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Pennsylvania
Merck and Co Inc
Original Assignee
Medical College of Pennsylvania
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Pennsylvania, Merck and Co Inc filed Critical Medical College of Pennsylvania
Application granted granted Critical
Publication of ES2198447T3 publication Critical patent/ES2198447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
ES95937658T 1994-10-27 1995-10-24 Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis. Expired - Lifetime ES2198447T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/330,518 US5607967A (en) 1994-10-27 1994-10-27 Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
US330518 1994-10-27

Publications (1)

Publication Number Publication Date
ES2198447T3 true ES2198447T3 (es) 2004-02-01

Family

ID=23290124

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95937658T Expired - Lifetime ES2198447T3 (es) 1994-10-27 1995-10-24 Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis.

Country Status (9)

Country Link
US (1) US5607967A (OSRAM)
EP (1) EP0786995B1 (OSRAM)
JP (1) JP3881011B2 (OSRAM)
AT (1) ATE241354T1 (OSRAM)
AU (1) AU705987B2 (OSRAM)
CA (1) CA2200886A1 (OSRAM)
DE (1) DE69530933T2 (OSRAM)
ES (1) ES2198447T3 (OSRAM)
WO (1) WO1996013257A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0726073A3 (en) * 1995-02-10 1998-07-08 Eduardo Samuel Bleiweiss Pharmaceutical compositions containing at least one of haloperidol, imipramine or trifluoroperazine
JP2001514663A (ja) * 1997-03-12 2001-09-11 エスモンド，ロバート ダブリュー． アルツハイマー病を処置または予防するための方法
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
HUP0100115A2 (hu) * 1997-10-28 2001-06-28 Schering Corp. Eljárás kóros vágy csökkentésére emlősökben
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6890716B1 (en) * 1998-05-07 2005-05-10 Howard Hughes Medical Institute Recombinant cell line and screening method for identifying agents which regulate apoptosis and tumor suppression
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2752800T3 (es) 2000-05-01 2020-04-06 Cerecin Inc Uso de triglicéridos de cadena media para el tratamiento y la prevención de la enfermedad del Parkinson resultante de un metabolismo neuronal reducido
GB0017951D0 (en) * 2000-07-22 2000-09-13 Univ Manchester Treatment of movement disorders
US20040053265A1 (en) * 2000-08-24 2004-03-18 Rainer Hipfel Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) * 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US20030185884A1 (en) * 2002-04-01 2003-10-02 Singh Nikhilesh Nihala Therapeutic agent delivery compositions for buccal cavity absorption of pilocarpine
ES2361924T3 (es) * 2002-12-20 2011-06-24 X-Ceptor Therapeutics, Inc. Derivados de isoquinolinona y su uso como agentes terapéuticos.
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2005101007A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with liver x receptor beta (lxrb)
EP2500017B1 (en) 2006-04-03 2017-09-06 Accera, Inc. Use of ketogenic compounds for treatment of age-associated memory impairment
AU2008251742A1 (en) * 2007-05-14 2008-11-20 Accera, Inc. Inhibitors of acetyl-CoA carboxylase for treatment of neuronal hypometabolism
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
CN102099033B (zh) * 2008-05-16 2012-10-24 阿克西斯股份有限公司 用于治疗纤维肌痛症的药物组合物
US9125881B2 (en) * 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
ES3041320T3 (en) * 2012-07-12 2025-11-11 Emalex Biosciences Inc Ecopipam for treatment of tourettes syndrome
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis
WO1994002108A1 (en) * 1992-07-24 1994-02-03 The Johns Hopkins University Chemotherapy for cancer

Also Published As

Publication number Publication date
ATE241354T1 (de) 2003-06-15
US5607967A (en) 1997-03-04
WO1996013257A1 (en) 1996-05-09
JPH10509139A (ja) 1998-09-08
EP0786995B1 (en) 2003-05-28
DE69530933D1 (de) 2003-07-03
EP0786995A1 (en) 1997-08-06
JP3881011B2 (ja) 2007-02-14
CA2200886A1 (en) 1996-05-09
AU3970095A (en) 1996-05-23
DE69530933T2 (de) 2004-02-12
EP0786995A4 (OSRAM) 1997-08-20
AU705987B2 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
ES2198447T3 (es) Uso del acido 5-(tetradeciloxi)-2-furancarboxilico para el tratamiento de la enfermedad de alzheimer o la psicosis.
Rozental et al. How to close a gap junction channel: Efficacies and potencies of uncoupling agents
Gwathmey et al. Nuclear angiotensin-(1–7) receptor is functionally coupled to the formation of nitric oxide
Maggio et al. Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance
Sepulveda et al. Effect of precipitated withdrawal on extracellular glutamate and aspartate in the nucleus accumbens of chronically morphine-treated rats: an in vivo microdialysis study
Benoist et al. RETRACTED: The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System
US20080019913A1 (en) Enkepahlin analogs with improved bioavailability
EP2697386B1 (en) Pepducin design and use
Kaczorowski et al. Developing molecular pharmacology of BK channels for therapeutic benefit
De Bundel et al. Trans-modulation of the somatostatin type 2A receptor trafficking by insulin-regulated aminopeptidase decreases limbic seizures
Li et al. Neurotensin excitation of serotonergic neurons in the rat nucleus raphe magnus: ionic and molecular mechanisms
Yang et al. Design, synthesis, and activity of an α-conotoxin LtIA fluorescent analogue
DE60020997T2 (de) Verbindungen zur Behandlung von abnormaler Glomerulusfiltration, Ductus arteriosus apertus und Osteoporose
US20090088403A1 (en) A3 adenosine receptors as targets for the modulation of central serotonergic signaling
EP1776121A2 (en) Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists
Gozes et al. A VIP hybrid antagonist: from developmental neurobiology to clinical applications
Han et al. Discovery of a small-molecule inhibitor of the TRIP8b–HCN interaction with efficacy in neurons
US5679518A (en) Method for finding transcription activators of the NER steroid hormone receptor
CN103052648A (zh) 用于抑制炎性和神经性疼痛的材料和方法
Florén et al. Multiple interaction sites of galnon trigger its biological effects
Fasciani et al. Distinctive binding properties of the negative allosteric modulator,[3H] SB269, 652, at recombinant dopamine D3 receptors
Leo et al. Trace amine-associated receptor 1 modulation of dopamine system
Denomme et al. N-(4-Bromo-2, 5-Dimethoxyphenethyl)-6-(4-Phenylbutoxy) Hexan-1-Amine (XOB): A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels
Scorza Kidney in a box: sviluppo di un modello renale in vitro per lo studio delle ciliopatie
Ruiz Utilizing Voltage-gated Calcium Channels to Assess the Activity of Cathinone Derivatives at Human Monoamine Transporters